Table 1 Relationship between SPON1 expression and clinicopathological factors in patients with ovarian cancer (n = 242)

Age

0.258

< 60

149

(61.6)

138

(62.7)

11

(50.0)

≥ 60

93

(38.4)

82

(37.3)

11

(50.0)

FIGO Stage

0.001

I/II

112

(46.3)

109

(49.5)

3

(13.6)

III/IV

130

(53.7)

111

(50.5)

19

(86.4)

Histological type

0.058

High-grade serous

83

(34.3)

71

(32.3)

12

(54.5)

Non-high-grade serous

159

(65.7)

149

(67.7)

10

(45.5)

 Low-grade serous

13

(5.4)

10

(4.5)

3

(13.6)

 Mucinous/Endometrioid

78

(32.2)

75

(34.1)

3

(13.6)

 Clear cell

56

(23.1)

54

(24.5)

2

(9.1)

 Others/unknown

12

(5.0)

10

(4.5)

2

(9.1)

T classification (pT)

0.011

1

95

(39.3)

92

(41.8)

3

(13.6)

2/3

147

(60.7)

128

(58.2)

19

(86.4)

Lymph node metastasis

1.000

(–)

123

(50.8)

117

(53.2)

6

(27.3)

(+)

40

(16.5)

39

(17.7)

1

(4.5)

Unknown

79

(32.6)

64

(29.1)

15

(68.2)

Distant metastasis

0.721

(–)

215

(88.8)

196

(89.1)

19

(86.4)

(+)

27

(11.2)

24

(10.9)

3

(13.6)

Peritoneal dissemination

< 0.001

(–)

123

(50.8)

120

(54.5)

3

(13.6)

(+)

119

(49.2)

100

(45.5)

19

(86.4)

Ascites cytology

0.418

(–)

70

(28.9)

65

(29.5)

5

(22.7)

(+)

85

(35.1)

75

(34.1)

10

(45.5)

Unknown

87

(36.0)

80

(36.4)

7

(31.8)

Type of surgery

0.009

Complete/optimal

116

(47.9)

111

(50.5)

5

(22.7)

Suboptimal

60

(24.8)

50

(22.7)

10

(45.5)

Unknown

66

(27.3)

59

(26.8)

7

(31.8)

CA-125 (U/mL)

0.085

< 35

30

(12.4)

30

(13.6)

0

(0.0)

≥ 35

204

(84.3)

183

(83.2)

21

(95.5)

Unknown

8

(3.3)

7

(3.2)

1

(4.5)

Platinum sensitivity

0.601

Sensitive

160

(66.1)

144

(65.5)

16

(72.7)

Resistance

61

(25.2)

57

(25.9)

4

(18.2)

No chemotherapy

21

(8.7)

19

(8.6)

2

(9.1)

Neoadjuvant chemotherapy

0.405

(–)

222

(91.7)

203

(92.3)

19

(86.4)

(+)

20

(8.3)

17

(7.7)

3

(13.6)

Recurrence

< 0.001

(–)

152

(62.8)

147

(66.8)

5

(22.7)

(+)

90

(37.2)

73

(33.2)

17

(77.3)